Long-term effects of cyclic therapy with iloprost in systemic sclerosis
Objective: To assess the long-term effects of cyclic infusion of iloprost, a derivative of prostacyclin, on Raynaud’s phenomenon- related symptoms and ischemic ulcers in patients with Systemic Sclerosis (SSc). Methods: A retrospective analysis of prospectively collected parameters in 59 consecutive...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2011-09-01
|
| Series: | Reumatismo |
| Online Access: | http://www.reumatismo.org/index.php/reuma/article/view/374 |
| _version_ | 1818572361659580416 |
|---|---|
| author | A. Grottolo A. Frigè E. Danieli M. Rossi M. Scarsi A. Zambruni P. Airò |
| author_facet | A. Grottolo A. Frigè E. Danieli M. Rossi M. Scarsi A. Zambruni P. Airò |
| author_sort | A. Grottolo |
| collection | DOAJ |
| description | Objective: To assess the long-term effects of cyclic infusion of iloprost, a derivative of prostacyclin, on Raynaud’s phenomenon- related symptoms and ischemic ulcers in patients with Systemic Sclerosis (SSc). Methods: A retrospective analysis of prospectively collected parameters in 59 consecutive SSc patients, followed at one institution, who were treated for a median time of 52 months with iloprost for severe Raynaud’s phenomenon and ischemic ulcers. Results: Among the 50 patients with ischemic ulcers at the start of therapy, 35 (70%) did not show lesions at the last observation. Despite therapy, four patients underwent amputations (two of forefoot, two of finger distal phalanges). Compared to the pre-treatment point, we observed: decrease of the Raynaud’s phenomenon VAS (p<0.001), and, in patients with diffuse cutaneous involvement, of the modified Rodnan skin thickness score (p=0.002). The Health Assessment Questionnaire was not significantly improved. Conclusion: Treatment with cyclic iloprost can control Raynaud’s phenomenon-related symptoms and ischemic ulcers in the large majority of patients with SSc. However, a disease-modifying effect of this therapy could not be demonstrated. |
| first_indexed | 2024-12-14T18:56:05Z |
| format | Article |
| id | doaj.art-f358a7394f54442bb72fa67a7cc258e2 |
| institution | Directory Open Access Journal |
| issn | 0048-7449 2240-2683 |
| language | English |
| last_indexed | 2024-12-14T18:56:05Z |
| publishDate | 2011-09-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Reumatismo |
| spelling | doaj.art-f358a7394f54442bb72fa67a7cc258e22022-12-21T22:51:05ZengPAGEPress PublicationsReumatismo0048-74492240-26832011-09-0160211411910.4081/reumatismo.2008.114Long-term effects of cyclic therapy with iloprost in systemic sclerosisA. GrottoloA. FrigèE. DanieliM. RossiM. ScarsiA. ZambruniP. AiròObjective: To assess the long-term effects of cyclic infusion of iloprost, a derivative of prostacyclin, on Raynaud’s phenomenon- related symptoms and ischemic ulcers in patients with Systemic Sclerosis (SSc). Methods: A retrospective analysis of prospectively collected parameters in 59 consecutive SSc patients, followed at one institution, who were treated for a median time of 52 months with iloprost for severe Raynaud’s phenomenon and ischemic ulcers. Results: Among the 50 patients with ischemic ulcers at the start of therapy, 35 (70%) did not show lesions at the last observation. Despite therapy, four patients underwent amputations (two of forefoot, two of finger distal phalanges). Compared to the pre-treatment point, we observed: decrease of the Raynaud’s phenomenon VAS (p<0.001), and, in patients with diffuse cutaneous involvement, of the modified Rodnan skin thickness score (p=0.002). The Health Assessment Questionnaire was not significantly improved. Conclusion: Treatment with cyclic iloprost can control Raynaud’s phenomenon-related symptoms and ischemic ulcers in the large majority of patients with SSc. However, a disease-modifying effect of this therapy could not be demonstrated.http://www.reumatismo.org/index.php/reuma/article/view/374 |
| spellingShingle | A. Grottolo A. Frigè E. Danieli M. Rossi M. Scarsi A. Zambruni P. Airò Long-term effects of cyclic therapy with iloprost in systemic sclerosis Reumatismo |
| title | Long-term effects of cyclic therapy with iloprost in systemic sclerosis |
| title_full | Long-term effects of cyclic therapy with iloprost in systemic sclerosis |
| title_fullStr | Long-term effects of cyclic therapy with iloprost in systemic sclerosis |
| title_full_unstemmed | Long-term effects of cyclic therapy with iloprost in systemic sclerosis |
| title_short | Long-term effects of cyclic therapy with iloprost in systemic sclerosis |
| title_sort | long term effects of cyclic therapy with iloprost in systemic sclerosis |
| url | http://www.reumatismo.org/index.php/reuma/article/view/374 |
| work_keys_str_mv | AT agrottolo longtermeffectsofcyclictherapywithiloprostinsystemicsclerosis AT afrige longtermeffectsofcyclictherapywithiloprostinsystemicsclerosis AT edanieli longtermeffectsofcyclictherapywithiloprostinsystemicsclerosis AT mrossi longtermeffectsofcyclictherapywithiloprostinsystemicsclerosis AT mscarsi longtermeffectsofcyclictherapywithiloprostinsystemicsclerosis AT azambruni longtermeffectsofcyclictherapywithiloprostinsystemicsclerosis AT pairo longtermeffectsofcyclictherapywithiloprostinsystemicsclerosis |